"Compared to the cost of annual treatment, the investment made in simple in-house systems, mobile data collection platforms and data transmission platforms would be a small cost," argues Ian Sanne.
"Community engagement is not disaster prevention, but a disaster management plan," says Morenike Ukpong-Folayan.
"People who are designing the studies, who are funding the studies, need to make [enrolling women] a priority," says Rena Patel, M.D.
The effect of even well-controlled HIV on the brain is not receiving enough attention. Now that people living with HIV no longer need to focus only on survival, quality-of-life issues must be addressed.
One subcutaneous dose of canakinumab, a monoclonal antibody to IL-1β, significantly reduced arterial inflammation in 10 individuals with well-controlled HIV.
A first-in-class HIV-1 capsid inhibitor interrupts replication at two steps of the viral lifecycle and has pharmacokinetic properties that may permit once-monthly or less frequent dosing.
"If there is compelling evidence that [a certain agent] works, we stop the trial straight away and let the world know what's going on," says Deborah Donnell, Ph.D.
Self-injected monotherapy with PRO 140, a monoclonal antibody that binds to the CCR5 receptor on CD4 cells, maintained viral suppression in 10 of 16 study participants for 41 to 123 weeks.
"Drug prices are too high and your access to your drugs is in danger. So, wake up and get ready!" says Lynda Dee of the Fair Pricing Coalition.
Among people starting their first antiretroviral therapy regimen, more advanced HIV disease and black race independently predicted severe weight gain through 96 weeks of follow-up.